NASDAQ:SPRO Spero Therapeutics (SPRO) Stock Price, News & Analysis $1.19 +0.03 (+2.59%) Closing price 10/6/2026 04:00 PM EasternExtended Trading$1.25 +0.06 (+4.62%) As of 04:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Spero Therapeutics Stock (NASDAQ:SPRO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Spero Therapeutics alerts:Sign Up Key Stats Today's Range$1.18▼$1.2450-Day Range$1.11▼$1.3652-Week Range$1.08▼$3.08Volume347,038 shsAverage Volume894,626 shsMarket Capitalization$69.31 millionP/E Ratio10.82Dividend YieldN/APrice Target$6.00Consensus RatingHold Company Overview Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious bacterial infections and other infectious diseases. The company’s research programs are aimed at addressing drug-resistant pathogens and conditions for which existing therapies may be limited. Spero’s pipeline has included tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic being developed for complicated urinary tract infections, including pyelonephritis. The company has also developed SPR720, an oral antibiotic candidate intended for the treatment of nontuberculous mycobacterial pulmonary disease, and SPR206, an intravenous antibiotic candidate targeting serious infections caused by multidrug-resistant Gram-negative bacteria. Founded in 2013 and headquartered in Cambridge, Massachusetts, Spero conducts its development activities primarily through clinical research and collaborations with industry and research partners. Its programs are designed for patients in the United States and other markets where resistant bacterial infections and difficult-to-treat infectious diseases represent significant healthcare challenges.AI Generated. May Contain Errors. Read More Spero Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreSPRO MarketRank™: Spero Therapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 97th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingHold Consensus RatingSpero Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 1 buy rating, 3 hold ratings, and no sell ratings.Upside PotentialSpero Therapeutics has a consensus price target of $6.00, representing about 404.2% upside from its current price of $1.19.Amount of Analyst CoverageSpero Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Spero Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Spero Therapeutics are expected to decrease in the coming year, from ($0.58) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spero Therapeutics is 10.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.75.Price to Earnings Ratio vs. SectorThe P/E ratio of Spero Therapeutics is 10.82, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.36.Price to Book Value per Share RatioSpero Therapeutics has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Spero Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.73% of the float of Spero Therapeutics has been sold short.Short Interest Ratio / Days to CoverSpero Therapeutics has a short interest ratio ("days to cover") of 3.06, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Spero Therapeutics has recently decreased by 19.33%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSpero Therapeutics does not currently pay a dividend.Dividend GrowthSpero Therapeutics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.42 News SentimentSpero Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Spero Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for SPRO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Spero Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Spero Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.90% of the stock of Spero Therapeutics is held by insiders.Percentage Held by Institutions25.60% of the stock of Spero Therapeutics is held by institutions.Read more about Spero Therapeutics' insider trading history. Receive SPRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPRO Stock News HeadlinesSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | globenewswire.comSpero Therapeutics consensus price target raised 25% to $5.10October 2, 2026 | msn.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 3, 2026 | globenewswire.comSpero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 2, 2026 | globenewswire.comSpero Therapeutics (SPRO) Q2 2026 Earnings Call TranscriptAugust 19, 2026 | finance.yahoo.comSpero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business UpdateAugust 13, 2026 | finanznachrichten.deSpero outlines cash runway into the second half of 2029 following $105M royalty financingAugust 13, 2026 | seekingalpha.comSee More Headlines SPRO Stock Analysis - Frequently Asked Questions How have SPRO shares performed this year? Spero Therapeutics' stock was trading at $2.33 at the start of the year. Since then, SPRO shares have decreased by 48.9% and is now trading at $1.19. How were Spero Therapeutics' earnings last quarter? Spero Therapeutics, Inc. (NASDAQ:SPRO) posted its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.01. Spero Therapeutics had a net margin of 24.90% and a trailing twelve-month return on equity of 16.17%. Read the conference call transcript. When did Spero Therapeutics IPO? Spero Therapeutics (SPRO) raised $82 million in an IPO on Thursday, November 2nd 2017. The company issued 5,500,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager. How do I buy shares of Spero Therapeutics? Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Spero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Spero Therapeutics investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Meta Platforms (META), NVIDIA (NVDA), Editas Medicine (EDIT) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/12/2026Today10/06/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 SPRO's financial health is in the Red zone, according to TradeSmith. SPRO has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SPRO CIK1701108 Websperotherapeutics.com Phone(857) 242-1600FaxN/AEmployees25Year Founded2013Price Target and Rating Average Price Target for Spero Therapeutics$6.00 High Price Target$6.00 Low Price Target$6.00 Potential Upside/Downside+404.2%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)$0.11 Trailing P/E Ratio10.82 Forward P/E RatioN/A P/E GrowthN/ANet Income$8.57 million Net Margins24.90% Pretax Margin16.26% Return on Equity16.17% Return on Assets12.57% Debt Debt-to-Equity RatioN/A Current Ratio6.12 Quick Ratio6.12 Sales & Book Value Annual Sales$66.80 million Price / Sales1.04 Cash Flow$0.16 per share Price / Cash Flow7.62 Book Value$1.05 per share Price / Book1.13Miscellaneous Outstanding Shares58,240,000Free Float56,546,000Market Cap$69.31 million OptionableOptionable Beta1.50 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:SPRO) was last updated on 10/7/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
